Skip to main content
SpringerLink
Log in

Ustekinumab als Therapeutikum bei Morbus Crohn

UNITI-IM-UNITI

Ustekinumab for the treatment of Crohn’s disease

UNITI-IM-UNITI

  • Klinische Studien
  • Published:
Der Internist Aims and scope Submit manuscript

An Erratum to this article was published on 20 March 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Gottlieb AB, Kalb RE, Langley RG et al (2014) Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol 13:1441–1448

    CAS  PubMed  Google Scholar 

  2. Papp KA, Griffiths CE, Gordon K et al (2013) Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 168:844–854

    Article  CAS  PubMed  Google Scholar 

  3. Sandborn WJ, Gasink C, Gao LL et al (2012) Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 367:1519–1528

    Article  CAS  PubMed  Google Scholar 

  4. Tillack C, Ehrmann LM, Freidrich M et al (2014) Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 treatment. Gut 63:567–577

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik für Gastroenterologie, Infektiologie, Rheumatologie, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, 12200, Hindenburgdamm 30, Berlin, Deutschland

    B. Siegmund

  2. Lippetal, Deutschland

    S. Nitschmann

Authors
  1. B. Siegmund
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Nitschmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Siegmund.

Ethics declarations

Interessenkonflikt

B. Siegmund und S. Nitschmann geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

M. Hallek, Köln

W. Lehmacher, Köln

N. Marx, Aachen

U. Müller-Ladner, Bad Nauheim

H. Wedemeyer, Hannover

M. Wehling, Mannheim

T.R. Weihrauch, Düsseldorf

Ein Erratum zu diesem Beitrag ist unter http://dx.doi.org/10.1007/s00108-017-0227-y zu finden.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Siegmund, B., Nitschmann, S. Ustekinumab als Therapeutikum bei Morbus Crohn. Internist 58, 424–426 (2017). https://doi.org/10.1007/s00108-017-0199-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-017-0199-y

Search

Navigation